UNSPSC 51263110: Idropranolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C16H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5U6118QYHK, chemically known as 1-((5,6-dihydro-1-naphthyl)oxy)-3-(isopropylamino)-2-propanol but generally known as idropranolol, which bears US NIH Compound Identifier 163314. European Medicines Agency schedules Idropranolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08122MIG.

UNSPSC 51263110 Idropranolol is a Commodity code that in state and local practice encompasses the procurement of pharmaceutical products and drug-related medical supplies, though recent opportunities tagged under this code show significant scope drift. Seminole County, Florida solicited naloxone and safe drug deactivation systems through an IFB in June 2026, and the Texas Health and Human Services Commission issued an RFI in April 2026 regarding direct-to-manufacturer prescription fulfillment programs—neither directly aligned with idropranolol as a specific pharmaceutical product. The issuing bodies span county health departments and state health agencies, suggesting the code is being used as a catch-all for pharmaceutical procurement rather than as a precision taxonomy entry for a particular beta-blocker medication.

Geographic activity in the recent record concentrates in Florida and Texas. Seminole County's naloxone IFB, posted June 30, 2026, with a response deadline of July 26, 2023 (a date inconsistency in the source), targets annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford; the contract includes a two-year initial term with a one-year renewal option and requires E-Verify compliance and drug-free workplace certification. The Texas HHS RFI, posted April 3, 2026, represents exploratory procurement activity rather than a formal competitive solicitation, seeking vendor information on direct-to-manufacturer prescription programs without a formal budget or timeline. These two opportunities suggest the code sees use in state and local health procurement but with minimal alignment to the specific pharmaceutical product the code nominally describes.